Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration

References

• Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol. 2011;7(6):323–331. doi:10.1038/nrneurol.2011.60
   PubMed Web of Science ®Google Scholar
• Bierer LM, Hof PR, Purohit DP, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer’s disease. Arch Neurol. 1995;52(1):81–88. doi:10.1001/archneur.1995.00540250089017
   PubMedGoogle Scholar
• Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111.
   PubMedGoogle Scholar
• Shaji S, Bose S, Verghese A. Prevalence of dementia in an urban population in Kerala, India. Br J Psychiatry. 2005;186(2):136–140. doi:10.1192/bjp.186.2.136
   PubMed Web of Science ®Google Scholar
• Peluso S, De Rosa A, De Lucia N, et al. Animal-assisted therapy in elderly patients: evidence and controversies in dementia and psychiatric disorders and future perspectives in other neurological diseases. J Geriatr Psychiatry Neurol. 2018;31(3):149–157. doi:10.1177/0891988718774634
   PubMed Web of Science ®Google Scholar
• Martinez-Horta S, Sampedro F, Horta-Barba A, et al. Structural brain correlates of dementia in Huntington’s disease. NeuroImage Clin. 2020;28:102415. doi:10.1016/j.nicl.2020.102415
   PubMed Web of Science ®Google Scholar
• Tschampa HJ, Neumann M, Zerr I, et al. Patients with Alzheimer’s disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2001;71(1):33–39. doi:10.1136/jnnp.71.1.33
   PubMed Web of Science ®Google Scholar
• Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386(10004):1672–1682. doi:10.1016/S0140-6736(15)00461-4
   PubMed Web of Science ®Google Scholar
• Pervin F, Edwards C, Lippa CF. Dementia with Lew body: impacts of surgery. Am J Alzheimers Dis Other Dement. 2016;31(1):5–17. doi:10.1177/1533317515581704
   PubMed Web of Science ®Google Scholar
• Mazucanti CH, Liu QR, Lang D, et al. Release of insulin produced by the choroid plexis is regulated by serotonergic signaling. JCI Insight. 2019;4(23). doi:10.1172/jci.insight.131682
   PubMed Web of Science ®Google Scholar
• Siso S, Jeffrey M, Gonzalez L. Sensory circumventricular organs in health and disease. Acta Neuropathol. 2010;120:689–705. doi:10.1007/s00401-010-0743-5
   PubMed Web of Science ®Google Scholar
• García-Cáceres C, Quarta C, Varela L, et al. Astrocytic insulin signaling couples brain glucose uptake with nutrient availability. Cell. 2016;166:867–880. doi:10.1016/j.cell.2016.07.028
   PubMed Web of Science ®Google Scholar
• Reno CM, Puente EC, Sheng Z, et al. Brain GLUT4 knockout mice have impaired glucose tolerance, decreased insulin sensitivity, and impaired hypoglycemiccounterregulation. Diabetes. 2017;66:587–597. doi:10.2337/db16-0917
   PubMed Web of Science ®Google Scholar
• Rojas FA, Hirata AE, Saad MJ. Regulation of insulin receptor substrate-2 tyrosine phosphorylation in animal models of insulin resistance. Endocrine. 2003;21:115–122. doi:10.1385/endo:21:2:115
   PubMed Web of Science ®Google Scholar
• Qiu J, Zhang C, Borgquist A, et al. Insulin excites anorexigenic proopiomelanocortin neurons via activation of canonical transient receptor potential channels. Cell Metab. 2014;19:682–693. doi:10.1016/j.cmet.2014.03.004
   PubMed Web of Science ®Google Scholar
• Ferreira LS, Fernandes CS, Vieira MN, De Felice FG. Insulin resistance in Alzheimer’s disease. Front Neurosci. 2018;12:830. doi:10.3389/fnins.2018.00830
   PubMed Web of Science ®Google Scholar
• Yun SP, Kam TI, Panicker N, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease. Nat Med. 2018;24(7):931–938. doi:10.1038/s41591-018-0051-5
   PubMed Web of Science ®Google Scholar
• Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson’s disease: mechanisms of action. Drug Discov Today. 2016;21(5):802–818. doi:10.1016/j.drudis.2016.01.013
   PubMed Web of Science ®Google Scholar
• Hunot S, Brugg B, Ricard D, et al. Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci. 1997;94(14):7531–7536. doi:10.1073/pnas.94.14.7531
   PubMed Web of Science ®Google Scholar
• Perry T, Lahiri DK, Chen D, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002;300(3):958–966. doi:10.1124/jpet.300.3.958
   PubMed Web of Science ®Google Scholar
• Querfurth HW, LaFerla FM. Mechanisms of disease. N Engl J Med. 2010;362(4):329–344. doi:10.1056/NEJMra0909142
   PubMed Web of Science ®Google Scholar
• Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H. Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol. 1998;96(2):116–122. doi:10.1007/s004010050870
   PubMed Web of Science ®Google Scholar
• Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther. 2011;3(1):1–3.
   PubMed Web of Science ®Google Scholar
• Chen JX, Yan SS. Role of mitochondrial amyloid-β in Alzheimer’s disease. J Alzheimers Dis. 2010;20(s2):S569–78. doi:10.3233/JAD-2010-100357
   PubMed Web of Science ®Google Scholar
• Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum Mol Genet. 2010;19(R1):R12–20. doi:10.1093/hmg/ddq160
   PubMed Web of Science ®Google Scholar
• Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019;14:5541. doi:10.2147/IJN.S200490
   PubMed Web of Science ®Google Scholar
• Guo JL, Lee VM. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem. 2011;286(17):15317–15331. doi:10.1074/jbc.M110.209296
   PubMed Web of Science ®Google Scholar
• Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. J Neurosci. 2013;33(3):1024–1037. doi:10.1523/JNEUROSCI.2642-12.2013
   PubMed Web of Science ®Google Scholar
• Medina M, Avila J. The role of extracellular Tau in the spreading of neurofibrillary pathology. Front Cell Neurosci. 2014;8:113. doi:10.3389/fncel.2014.00113
   PubMed Web of Science ®Google Scholar
• McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269. doi:10.1016/j.jalz.2011.03.005
   PubMed Web of Science ®Google Scholar
• Markowitsch HJ, Staniloiu A. Amnesic disorders. Lancet. 2012;380(9851):1429–1440. doi:10.1016/S0140-6736(11)61304-4
   PubMed Web of Science ®Google Scholar
• Aljanabi NM, Mamtani S, Al-Ghuraibawi MM, Yadav S, Nasr L. Alzheimer’s and hyperglycemia: role of the insulin signaling pathway and GSK-3 inhibition in paving a path to dementia. Cureus. 2020;12(2):e6885.
   PubMed Web of Science ®Google Scholar
• Zola-Morgan S, Squire LR, Amaral DG. Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. J Neurosci. 1986;6(10):2950–2967. doi:10.1523/JNEUROSCI.06-10-02950.1986
   PubMed Web of Science ®Google Scholar
• Peters F, Collette F, Degueldre C, Sterpenich V, Majerus S, Salmon E. The neural correlates of verbal short-term memory in Alzheimer’s disease: an fMRI study. Brain. 2009;132(7):1833–1846. doi:10.1093/brain/awp075
   PubMed Web of Science ®Google Scholar
• Abbott MA, Wells DG, Fallon JR. The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J Neurosci. 1999;19(17):7300–7308. doi:10.1523/JNEUROSCI.19-17-07300.1999
   PubMed Web of Science ®Google Scholar
• Skeberdis VA, Lan JY, Zheng X, Zukin RS, Bennett MV. Insulin promotes rapid delivery of N-methyl-D-aspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci. 2001;98(6):3561–3566. doi:10.1073/pnas.051634698
   PubMed Web of Science ®Google Scholar
• Bingham EM, Hopkins D, Smith D, et al. The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. Diabetes. 2002;51(12):3384–3390. doi:10.2337/diabetes.51.12.3384
   PubMed Web of Science ®Google Scholar
• Craft S, Asthana S, Cook DG, et al. Insulin dose–response effects on memory and plasma amyloid precursor protein in Alzheimer’s disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology. 2003;28(6):809–822. doi:10.1016/S0306-4530(02)00087-2
   PubMed Web of Science ®Google Scholar
• Townsend M, Mehta T, Selkoe DJ. Soluble Aβ inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem. 2007;282(46):33305–33312. doi:10.1074/jbc.M610390200
   PubMed Web of Science ®Google Scholar
• De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers. Proc Natl Acad Sci. 2009;106(6):1971–1976. doi:10.1073/pnas.0809158106
   PubMed Web of Science ®Google Scholar
• Lee CC, Kuo YM, Huang CC, Hsu KS. Insulin rescues amyloid β-induced impairment of hippocampal long-term potentiation. Neurobiol Aging. 2009;30(3):377–387. doi:10.1016/j.neurobiolaging.2007.06.014
   PubMed Web of Science ®Google Scholar
• Sato S, Tatebayashi Y, Akagi T, et al. Aberrant tau phosphorylation by glycogen synthase kinase-3β and JNK3 induces oligomeric tau fibrils in COS-7 cells. J Biol Chem. 2002;277(44):42060–42065. doi:10.1074/jbc.M202241200
   PubMed Web of Science ®Google Scholar
• Harman D. Alzheimer’s disease: role of aging in pathogenesis. Ann N Y Acad Sci. 2002;959(1):384–395. doi:10.1111/j.1749-6632.2002.tb02109.x
   PubMed Web of Science ®Google Scholar
• Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J Alzheimers Dis. 2005;8(3):247–268. doi:10.3233/JAD-2005-8304
   PubMed Web of Science ®Google Scholar
• Lesort M, Johnson GV. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience. 2000;99(2):305–316. doi:10.1016/S0306-4522(00)00200-1
   PubMed Web of Science ®Google Scholar
• Planel E, Richter KE, Nolan CE, et al. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci. 2007;27(12):3090–3097. doi:10.1523/JNEUROSCI.4854-06.2007
   PubMed Web of Science ®Google Scholar
• Mi K, Johnson GV. The role of tau phosphorylation in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res. 2006;3(5):449–463. doi:10.2174/156720506779025279
   PubMedGoogle Scholar
• Alonso AD, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci. 2001;98(12):6923–6928. doi:10.1073/pnas.121119298
   PubMed Web of Science ®Google Scholar
• Planel E, Tatebayashi Y, Miyasaka T, et al. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci. 2007;27(50):13635–13648. doi:10.1523/JNEUROSCI.3949-07.2007
   PubMed Web of Science ®Google Scholar
• Schubert M, Brazil DP, Burks DJ, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci. 2003;23(18):7084–7092. doi:10.1523/JNEUROSCI.23-18-07084.2003
   PubMed Web of Science ®Google Scholar
• Schubert M, Gautam D, Surjo D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci. 2004;101(9):3100–3105. doi:10.1073/pnas.0308724101
   PubMed Web of Science ®Google Scholar
• Long C, Grueter CE, Song K, et al. Ataxia and Purkinje cell degeneration in mice lacking the CAMTA1 transcription factor. Proc Natl Acad Sci. 2014;111(31):11521–11526. doi:10.1073/pnas.1411251111
   PubMed Web of Science ®Google Scholar
• Manczak M, Park BS, Jung Y, Reddy PH. Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease. Neuromolecular Med. 2004;5(2):147–162. doi:10.1385/NMM:5:2:147
   PubMed Web of Science ®Google Scholar
• Zhu X, Smith MA, Perry G, Aliev G. Mitochondrial failures in Alzheimer’s disease. Am J Alzheimers Dis Other Dement. 2004;19(6):345–352. doi:10.1177/153331750401900611
   PubMedGoogle Scholar
• Hirai K, Aliev G, Nunomura A, et al. Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci. 2001;21(9):3017–3023. doi:10.1523/JNEUROSCI.21-09-03017.2001
   PubMed Web of Science ®Google Scholar
• Rademakers R, Cruts M, Van Broeckhoven C. Genetics of early-onset Alzheimer dementia. Sci World J. 2003;3:497–519. doi:10.1100/tsw.2003.39
   Google Scholar
• German DC, Eisch AJ. Mouse models of Alzheimer’s disease: insight into treatment. Rev Neurosci. 2004;15(5):353–370. doi:10.1515/REVNEURO.2004.15.5.353
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med. 2004;140(8):627–638. doi:10.7326/0003-4819-140-8-200404200-00047
   PubMed Web of Science ®Google Scholar
• Bhutada P, Mundhada Y, Humane V, et al. Agmatine, an endogenous ligand of imidazoline receptor protects against memory impairment and biochemical alterations in streptozotocin-induced diabetic rats. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(1):96–105. doi:10.1016/j.pnpbp.2012.01.009
   PubMed Web of Science ®Google Scholar
• Richard F, Pasquier F. Can the treatment of vascular risk factors slow cognitive decline in Alzheimer’s disease patients? J Alzheimers Dis. 2012;32(3):765–772. doi:10.3233/JAD-2012-121012
   PubMed Web of Science ®Google Scholar
• Cao Q, Jiang K, Zhang M, et al. Brain glucose metabolism and neuropsychological test in patients with mild cognitive impairment. Chin Med J. 2003;116(8):1235–1238.
   PubMed Web of Science ®Google Scholar
• Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH. Ageing and diabetes: implications for brain function. Eur J Pharmacol. 2002;441(1–2):1–4. doi:10.1016/S0014-2999(02)01486-3
   PubMed Web of Science ®Google Scholar
• Zhao WQ, Chen H, Quon MJ, Alkon DL. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol. 2004;490(1–3):71–81. doi:10.1016/j.ejphar.2004.02.045
   PubMed Web of Science ®Google Scholar
• Kamal A, Biessels GJ, Gispen WH, Ramakers GM. Synaptic transmission changes in the pyramidal cells of the hippocampus in streptozotocin-induced diabetes mellitus in rats. Brain Res. 2006;1073:276–280. doi:10.1016/j.brainres.2005.12.070
   PubMed Web of Science ®Google Scholar
• Cardoso S, Santos MS, Seiça R, Moreira PI. Cortical and hippocampal mitochondria bioenergetics and oxidative status during hyperglycemia and/or insulin-induced hypoglycemia. Biochim Biophys Acta Mol Basis Dis. 2010;1802(11):942–951. doi:10.1016/j.bbadis.2010.07.001
   Web of Science ®Google Scholar
• Zhao WQ, Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis. 2009;1792(5):482–496.
   Web of Science ®Google Scholar
• Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404(6779):787–790. doi:10.1038/35008121
   PubMed Web of Science ®Google Scholar
• Park HR, Park M, Choi J, Park KY, Chung HY, Lee J. A high-fat diet impairs neurogenesis: involvement of lipid peroxidation and brain-derived neurotrophic factor. Neurosci Lett. 2010;482(3):235–239. doi:10.1016/j.neulet.2010.07.046
   PubMed Web of Science ®Google Scholar
• Parikh V, Kozak R, Martinez V, Sarter M. Prefrontal acetylcholine release controls cue detection on multiple timescales. Neuron. 2007;56(1):141–154. doi:10.1016/j.neuron.2007.08.025
   PubMed Web of Science ®Google Scholar
• Hasselmo ME, Sarter M. Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology. 2011;36(1):52–73. doi:10.1038/npp.2010.104
   PubMed Web of Science ®Google Scholar
• Pakiam AS, Bergeron C, Lang AE. Diffuse Lewy body disease presenting as multiple system atrophy. Can J Neurol Sci. 1999;26(2):127–131.
   PubMed Web of Science ®Google Scholar
• Mark MH, Sage JI, Dickson DW, et al. Meige syndrome in the spectrum of Lewy body disease. Neurology. 1994;44(8):1432. doi:10.1212/WNL.44.8.1432
   PubMed Web of Science ®Google Scholar
• Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res. 1979;171(2):319–327. doi:10.1016/0006-8993(79)90336-6
   PubMed Web of Science ®Google Scholar
• Court JA, Perry EK. Dementia: the neurochemical basis of putative transmitter orientated therapy. Pharmacol Ther. 1991;52(3):423–443. doi:10.1016/0163-7258(91)90035-K
   PubMed Web of Science ®Google Scholar
• Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev. 2008;29(4):494–511. doi:10.1210/er.2007-0034
   PubMed Web of Science ®Google Scholar
• Auer RN. Hypoglycemic brain damage. In: Acute Neuronal Injury; 2018:175–188.
   Google Scholar
• Sonnewald U, McKenna M. Metabolic compartmentation in cortical synaptosomes: influence of glucose and preferential incorporation of endogenous glutamate into GABA. Neurochem Res. 2002;27(1):43–50. doi:10.1023/A:1014846404492
   PubMed Web of Science ®Google Scholar
• Frigerio F, Casimir M, Carobbio S, Maechler P. Tissue specificity of mitochondrial glutamate pathways and the control of metabolic homeostasis. Biochim Biophys Acta Bioenerg. 2008;1777(7–8):965–972. doi:10.1016/j.bbabio.2008.04.031
   Web of Science ®Google Scholar
• Bak LK, Schousboe A, Waagepetersen HS. The glutamate/GABA‐glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem. 2006;98(3):641–653. doi:10.1111/j.1471-4159.2006.03913.x
   PubMed Web of Science ®Google Scholar
• Alberdi E, Sánchez-Gómez MV, Cavaliere F, et al. Amyloid β oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium. 2010;47(3):264–272. doi:10.1016/j.ceca.2009.12.010
   PubMed Web of Science ®Google Scholar
• Gundersen V, Fonnum F, Ottersen OP, Storm-Mathisen J. Redistribution of neuroactive amino acids in hippocampus and striatum during hypoglycemia: a quantitative immunogold study. J Cereb Blood Flow Metab. 2001;21(1):41–51. doi:10.1097/00004647-200101000-00006
   PubMed Web of Science ®Google Scholar
• Clementi F. Distribution of nicotinic subtypes in human brain. Alzheimer Dis Assoc Disord. 1995;9 Suppl 2:6–14. doi:10.1097/00002093-199501002-00003
   PubMed Web of Science ®Google Scholar
• Bartus RT, Dean R, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217(4558):408–414. doi:10.1126/science.7046051
   PubMed Web of Science ®Google Scholar
• Court JA, Piggott MA, Lloyd S, et al. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease and in relation to neuroleptic medication. Neuroscience. 2000;98(1):79–87. doi:10.1016/S0306-4522(00)00071-3
   PubMed Web of Science ®Google Scholar
• Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution. Brain. 1999;122(8):1449–1468. doi:10.1093/brain/122.8.1449
   PubMed Web of Science ®Google Scholar
• Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer’s disease. Psychopharmacology. 1992;108(4):485–494. doi:10.1007/BF02247426
   PubMed Web of Science ®Google Scholar
• Levin ED, Briggs SJ, Christopher NC, Rose JE. Persistence of chronic nicotine-induced cognitive facilitation. Behav Neural Biol. 1992;58(2):152–158. doi:10.1016/0163-1047(92)90399-O
   PubMedGoogle Scholar
• Levin ED, Bettegowda C, Blosser J, Gordon J. AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol. 1999;10(6–7):675–680. doi:10.1097/00008877-199911000-00014
   PubMed Web of Science ®Google Scholar
• Alkondon M, Rocha ES, Maelicke A, Albuquerque EX. Diversity of nicotinic acetylcholine receptors in rat brain. V. alpha-Bungarotoxin-sensitive nicotinic receptors in olfactory bulb neurons and presynaptic modulation of glutamate release. J Pharmacol Exp Ther. 1996;278(3):1460–1471.
   PubMed Web of Science ®Google Scholar
• Lippa CF, Smith TW, Perry E. Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology. J Neural Transm. 1999;106(5):525–535. doi:10.1007/s007020050176
   PubMed Web of Science ®Google Scholar
• Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267(5203):1456–1462. doi:10.1126/science.7878464
   PubMed Web of Science ®Google Scholar
• Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998;102(4):783–791. doi:10.1172/JCI2425
   PubMed Web of Science ®Google Scholar
• Zhang W, Khanna P, Chan LL, Campbell G, Ansari NH. Diabetes-induced apoptosis in rat kidney. Biochem Mol Med. 1997;61(1):58–62. doi:10.1006/bmme.1997.2592
   PubMedGoogle Scholar
• Stefani L, Burke RE, Greene LA. Apoptosis in neurodegenerative disorders. Curr Opin Neurol. 1997;10:299–305. doi:10.1097/00019052-199708000-00004
   PubMed Web of Science ®Google Scholar
• White BC, Sullivan JM, DeGracia DJ, et al. Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J Neurol Sci. 2000;179(1–2):1–33. doi:10.1016/s0022-510x(00)00386-5
   PubMed Web of Science ®Google Scholar
• Resnicoff M, Burgaud JL, Rotman HL, Abraham D, Baserga R. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res. 1995;55(17):3739–3741.
   PubMed Web of Science ®Google Scholar
• Zhang W, Ghetti B, Lee WH. Decreased IGF-I gene expression during the apoptosis of Purkinje cells in pcd mice. Dev Brain Res. 1997;98(2):164–176. doi:10.1016/S0165-3806(96)00168-X
   PubMedGoogle Scholar
• Li ZG, Zhang W, Grunberger G, Sima AA. Hippocampal neuronal apoptosis in type 1 diabetes. Brain Res. 2002;946(2):221–231. doi:10.1016/S0006-8993(02)02887-1
   PubMed Web of Science ®Google Scholar
• Folch J, Olloquequi J, Ettcheto M, et al. The involvement of peripheral and brain insulin resistance in late onset Alzheimer’s dementia. Front Aging Neurosci. 2019;11:236. doi:10.3389/fnagi.2019.00236
   PubMed Web of Science ®Google Scholar
• Kalaria RN. Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer’s disease. Acta Neuropathol. 2016;131(5):659–685. doi:10.1007/s00401-016-1571-z
   PubMed Web of Science ®Google Scholar
• Xiong Y, Zhou H, Zhang L. Influences of hyperthermia-induced seizures on learning, memory and phosphorylative state of CaMKIIα in rat hippocampus. Brain Res. 2014;1557:190–200. doi:10.1016/j.brainres.2014.02.026
   PubMed Web of Science ®Google Scholar
• Sairanen T, Karjalainen-Lindsberg ML, Paetau A, Ijäs P, Lindsberg PJ. Apoptosis dominant in the periinfarct area of human ischaemic stroke—a possible target of antiapoptotic treatments. Brain. 2006;129(1):189–199. doi:10.1093/brain/awh645
   PubMed Web of Science ®Google Scholar
• Viswanathan A, Gray F, Bousser MG, Baudrimont M, Chabriat H. Cortical neuronal apoptosis in CADASIL. Stroke. 2006;37(11):2690–2695. doi:10.1161/01.STR.0000245091.28429.6a
   PubMed Web of Science ®Google Scholar
• Wang XX, Zhang B, Xia R, Jia QY. Inflammation, apoptosis and autophagy as critical players in vascular dementia. Eur Rev Med Pharmacol Sci. 2020;24(18):9601–9614. doi:10.26355/eurrev_202009_23048
   PubMed Web of Science ®Google Scholar
• Kalaria RN. Cerebrovascular disease and mechanisms of cognitive impairment: evidence from clinicopathological studies in humans. Stroke. 2012;43(9):2526–2534. doi:10.1161/STROKEAHA.112.655803
   PubMed Web of Science ®Google Scholar
• Mungas D, Jagust WJ, Reed BR, et al. MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer’s disease. Neurology. 2001;57(12):2229–2235. doi:10.1212/WNL.57.12.2229
   PubMed Web of Science ®Google Scholar
• Ashford ML, Boden PR, Treherne JM. Glucose-induced excitation of hypothalamic neurones is mediated by ATP-sensitive K+ channels. Pflügers Archiv. 1990;415(4):479–483. doi:10.1007/BF00373626
   PubMed Web of Science ®Google Scholar
• Miki T, Liss B, Minami K, et al. ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat Neurosci. 2001;4(5):507–512. doi:10.1038/87455
   PubMed Web of Science ®Google Scholar
• Kang L, Routh VH, Kuzhikandathil EV, Gaspers LD, Levin BE. Physiological and molecular characteristics of rat hypothalamic ventromedial nucleus glucosensing neurons. Diabetes. 2004;53(3):549–559. doi:10.2337/diabetes.53.3.549
   PubMed Web of Science ®Google Scholar
• Ibrahim N, Bosch MA, Smart JL, et al. Hypothalamic proopiomelanocortin neurons are glucose responsive and express KATP channels. Endocrinology. 2003;144(4):1331–1340. doi:10.1210/en.2002-221033
   PubMed Web of Science ®Google Scholar
• Popa-Wagner A, Buga AM, Popescu B, Muresanu D. Vascular cognitive impairment, dementia, aging and energy demand. A vicious cycle. J Neural Transm. 2015;122(1):47–54. doi:10.1007/s00702-013-1129-3
   Web of Science ®Google Scholar
• Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol. 2010;119(4):421–433. doi:10.1007/s00401-010-0654-5
   PubMed Web of Science ®Google Scholar
• Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke. 2003;34(2):335–337. doi:10.1161/01.STR.0000054050.51530.76
   PubMed Web of Science ®Google Scholar
• Pluta R, Jolkkonen J, Cuzzocrea S, Pedata F, Cechetto D, Popa-Wagner A. Cognitive impairment with vascular impairment and degeneration. Curr Neurovasc Res. 2011;8(4):342–350. doi:10.2174/156720211798120981
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178–201. doi:10.1016/j.neuron.2008.01.003
   PubMed Web of Science ®Google Scholar
• Kasuga M, Karlsson FA, Kahn CR. Insulin stimulates the phosphorylation of the 95,000-dalton subunit of its own receptor. Science. 1982;215(4529):185–187. doi:10.1126/science.7031900
   PubMed Web of Science ®Google Scholar
• Pocai A, Obici S, Schwartz GJ, Rossetti L. A brain-liver circuit regulates glucose homeostasis. Cell Metab. 2005;1(1):53–61. doi:10.1016/j.cmet.2004.11.001
   PubMed Web of Science ®Google Scholar
• Filippi BM, Yang CS, Tang C, Lam TK. Insulin activates Erk1/2 signaling in the dorsal vagal complex to inhibit glucose production. Cell Metab. 2012;16(4):500–510. doi:10.1016/j.cmet.2012.09.005
   PubMed Web of Science ®Google Scholar
• Rossi J, Balthasar N, Olson D, et al. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab. 2011;13(2):195–204. doi:10.1016/j.cmet.2011.01.010
   PubMed Web of Science ®Google Scholar
• Berglund ED, Liu T, Kong X, et al. Melanocortin 4 receptors in autonomic neurons regulate thermogenesis and glycemia. Nat Neurosci. 2014;17(7):911–913. doi:10.1038/nn.3737
   PubMed Web of Science ®Google Scholar
• Hill JW, Elias CF, Fukuda M, et al. Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility. Cell Metab. 2010;11(4):286–297. doi:10.1016/j.cmet.2010.03.002
   PubMed Web of Science ®Google Scholar
• Könner AC, Janoschek R, Plum L, et al. Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metab. 2007;5(6):438–449. doi:10.1016/j.cmet.2007.05.004
   PubMed Web of Science ®Google Scholar
• Ruud J, Steculorum SM, Brüning JC. Neuronal control of peripheral insulin sensitivity and glucose metabolism. Nat Commun. 2017;8(1):1–2. doi:10.1038/ncomms15259
   PubMed Web of Science ®Google Scholar
• Freeman AM, Pennings N. Insulin resistance. In: StatPearls [Internet]; 2021.
   Google Scholar
• Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and Alzheimer’s disease: shared pathology and treatment? Br J Clin Pharmacol. 2011;71(3):365–376. doi:10.1111/j.1365-2125.2010.03830.x
   PubMed Web of Science ®Google Scholar
• Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res. 2008;102(4):401–414. doi:10.1161/CIRCRESAHA.107.165472
   PubMed Web of Science ®Google Scholar
• Cooper SA, Whaley-Connell A, Habibi J, et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol. 2007;293(4):H2009–23. doi:10.1152/ajpheart.00522.2007
   PubMed Web of Science ®Google Scholar
• Sowers JR, Stump CS. Insights into the biology of diabetic vascular disease: what’s new? Am J Hypertens. 2004;17(S2):2S–6S. doi:10.1016/j.amjhyper.2003.08.015
   PubMed Web of Science ®Google Scholar
• Brehm A, Krssak M, Schmid AI, Nowotny P, Waldhäusl W, Roden M. Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. Diabetes. 2006;55(1):136–140. doi:10.2337/diabetes.55.01.06.db05-1286
   PubMed Web of Science ®Google Scholar
• Ritz P, Berrut G. Mitochondrial function, energy expenditure, aging and insulin resistance. Diabetes Metab. 2005;31:5S67–73. doi:10.1016/S1262-3636(05)73654-5
   PubMed Web of Science ®Google Scholar
• Frisard M, Ravussin E. Energy metabolism and oxidative stress: impact on the metabolic syndrome and the aging process. Endocrine. 2006;29(1):27–32. doi:10.1385/ENDO:29:1:27
   PubMed Web of Science ®Google Scholar
• Befroy DE, Petersen KF, Dufour S, et al. Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes. 2007;56(5):1376–1381. doi:10.2337/db06-0783
   PubMed Web of Science ®Google Scholar
• Krssak MF, Petersen KF, Dresner A, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia. 1999;42(1):113–116. doi:10.1007/s001250051123
   PubMed Web of Science ®Google Scholar
• Mogensen M, Sahlin K, Fernström M, et al. Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes. 2007;56(6):1592–1599. doi:10.2337/db06-0981
   PubMed Web of Science ®Google Scholar
• Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2007;116(4):434–448. doi:10.1161/CIRCULATIONAHA.107.702795
   PubMed Web of Science ®Google Scholar
• Nisoli E, Clementi E, Carruba MO, Moncada S. Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome? Circ Res. 2007;100(6):795–806. doi:10.1161/01.RES.0000259591.97107.6c
   PubMed Web of Science ®Google Scholar
• Wiederkehr A, Wollheim CB. Minireview: implication of mitochondria in insulin secretion and action. Endocrinology. 2006;147(6):2643–2649. doi:10.1210/en.2006-0057
   PubMed Web of Science ®Google Scholar
• Aliev G, Gasimov E, Obrenovich ME, et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: implication in the pathogenesis of Alzheimer’s disease. Vasc Health Risk Manag. 2008;4(3):721. doi:10.2147/VHRM.S2608
   PubMedGoogle Scholar
• Abdul HM, Sultana R, Clair DK, Markesbery WR, Butterfield DA. Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Free Radic Biol Med. 2008;45(10):1420–1425. doi:10.1016/j.freeradbiomed.2008.08.012
   PubMed Web of Science ®Google Scholar
• Coskun PE, Wyrembak J, Derbereva O, et al. Systemic mitochondrial dysfunction and the etiology of Alzheimer’s disease and down syndrome dementia. J Alzheimers Dis. 2010;20(s2):S293–310. doi:10.3233/JAD-2010-100351
   PubMed Web of Science ®Google Scholar
• Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006;116(3):615–622. doi:10.1172/JCI27794
   PubMed Web of Science ®Google Scholar
• Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes. 2005;54(1):8–14. doi:10.2337/diabetes.54.1.8
   PubMed Web of Science ®Google Scholar
• Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator–activated receptor γ coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest. 2000;106(7):847–856. doi:10.1172/JCI10268
   PubMed Web of Science ®Google Scholar
• Baar K, Wende AR, Jones TE, et al. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC‐1. FASEB J. 2002;16(14):1879–1886. doi:10.1096/fj.02-0367com
   PubMed Web of Science ®Google Scholar
• Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology. 2004;63(4):658–663. doi:10.1212/01.WNL.0000134666.64593.BA
   PubMed Web of Science ®Google Scholar
• Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3(3):169–178. doi:10.1016/S1474-4422(04)00681-7
   PubMed Web of Science ®Google Scholar
• Gad ES, Zaitone SA, Moustafa YM. Pioglitazone and exenatide enhance cognition and downregulate hippocampal beta amyloid oligomer and microglia expression in insulin-resistant rats. Can J Physiol Pharmacol. 2016;94(8):819–828. doi:10.1139/cjpp-2015-0242
   PubMed Web of Science ®Google Scholar
• Carvalho C, Correia SC, Santos RX, et al. Role of mitochondrial-mediated signaling pathways in Alzheimer disease and hypoxia. J Bioenerg Biomembr. 2009;41(5):433. doi:10.1007/s10863-009-9247-1
   PubMed Web of Science ®Google Scholar
• Yang C, DeVisser A, Martinez JA, et al. Retracted: differential impact of diabetes and hypertension in the brain: adverse effects in white matter. Neurobiol Dis. 2011;42(3):446–458. doi:10.1016/j.nbd.2011.02.007
   PubMed Web of Science ®Google Scholar
• Puddu A, Mach F, Nencioni A, Viviani GL, Montecucco F. An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. Mediators Inflamm. 2013;2013:1–9. doi:10.1155/2013/591056
   Web of Science ®Google Scholar
• Mao H, Liu B. Synergistic microglial reactive oxygen species generation induced by pesticides lindane and dieldrin. Neuroreport. 2008;19(13):1317–1320. doi:10.1097/WNR.0b013e32830b3677
   PubMed Web of Science ®Google Scholar
• Kemp K, Griffiths J, Campbell S, Lovell K. An exploration of the follow-up up needs of patients with inflammatory bowel disease. J Crohns Colitis. 2013;7(9):e386–95. doi:10.1016/j.crohns.2013.03.001
   PubMed Web of Science ®Google Scholar
• Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer’s disease. Neurobiol Aging. 2001;22(6):903–908. doi:10.1016/S0197-4580(01)00287-1
   PubMed Web of Science ®Google Scholar
• Zilka N, Ferencik M, Hulin I. Neuroinflammation in Alzheimer’s disease: protector or promoter? Bratisl Lek Listy. 2006;107(9–10):374–383.
   PubMedGoogle Scholar
• Chen Y, Liang Z, Blanchard J, et al. A non-transgenic mouse model (icv-STZ mouse) of Alzheimer’s disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol. 2013;47(2):711–725. doi:10.1007/s12035-012-8375-5
   PubMed Web of Science ®Google Scholar
• Banks WA, Owen JB, Erickson MA. Insulin in the brain: there and back again. Pharmacol Ther. 2012;136(1):82–93. doi:10.1016/j.pharmthera.2012.07.006
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang J, Zhang B, Gong CX. Targeting insulin signaling for the treatment of Alzheimer’s disease. Curr Top Med Chem. 2016;16(5):485–492. doi:10.2174/1568026615666150813142423
   PubMed Web of Science ®Google Scholar
• Bouvier DS, Murai KK. Synergistic actions of microglia and astrocytes in the progression of Alzheimer’s disease. J Alzheimers Dis. 2015;45(4):1001–1014. doi:10.3233/JAD-143156
   PubMed Web of Science ®Google Scholar
• Guo Z, Chen Y, Mao YF, et al. Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer’s rat model. Sci Rep. 2017;7(1):1–2. doi:10.1038/s41598-016-0028-x
   PubMed Web of Science ®Google Scholar
• Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA. Insulin-resistant brain state: the culprit in sporadic Alzheimer’s disease? Ageing Res Rev. 2011;10(2):264–273. doi:10.1016/j.arr.2011.01.001
   PubMed Web of Science ®Google Scholar
• Correia SC, Santos RX, Carvalho C, et al. Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer’s disease and diabetes interrelation. Brain Res. 2012;1441:64–78. doi:10.1016/j.brainres.2011.12.063
   PubMed Web of Science ®Google Scholar
• Suh YH, Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer’s disease (vol 54, pg 469, 2002). Pharmacol Rev. 2006;58(2):280.
   Web of Science ®Google Scholar
• Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. Biochim Biophys Acta Mol Basis Dis. 2010;1802(1):2–10. doi:10.1016/j.bbadis.2009.10.006
   PubMed Web of Science ®Google Scholar
• Bonda DJ, Wang X, Perry G, et al. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology. 2010;59(4–5):290–294. doi:10.1016/j.neuropharm.2010.04.005
   PubMed Web of Science ®Google Scholar
• Cameron B, Landreth GE. Inflammation, microglia, and Alzheimer’s disease. Neurobiol Dis. 2010;37(3):503–509. doi:10.1016/j.nbd.2009.10.006
   PubMed Web of Science ®Google Scholar
• Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol. 2002;68(3):209–245. doi:10.1016/s0301-0082(02)00079-5
   PubMed Web of Science ®Google Scholar
• Jin K, Peel AL, Mao XO, et al. Increased hippocampal neurogenesis in Alzheimer’s disease. Proc Natl Acad Sci. 2004;101(1):343–347. doi:10.1073/pnas.2634794100
   PubMed Web of Science ®Google Scholar
• Vadodaria KC, Gage FH. SnapShot: adult hippocampal neurogenesis. Cell. 2014;156(5):1114. doi:10.1016/j.cell.2014.02.029
   PubMed Web of Science ®Google Scholar
• Djurfeldt M, Hjorth J, Eppler JM, et al. Run-time interoperability between neuronal network simulators based on the MUSIC framework. Neuroinformatics. 2010;8(1):43–60. doi:10.1007/s12021-010-9064-z
   PubMed Web of Science ®Google Scholar
• Kraska A, Santin MD, Dorieux O, et al. In vivo cross-sectional characterization of cerebral alterations induced by intracerebroventricular administration of streptozotocin. PLoS One. 2012;7(9):e46196. doi:10.1371/journal.pone.0046196
   PubMed Web of Science ®Google Scholar
• Javed H, Khan MM, Ahmad A, et al. Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type. Neuroscience. 2012;210:340–352. doi:10.1016/j.neuroscience.2012.02.046
   PubMed Web of Science ®Google Scholar
• Qu ZQ, Zhou Y, Zeng YS, et al. Protective effects of a Rhodiola crenulata extract and salidroside on hippocampal neurogenesis against streptozotocin-induced neural injury in the rat. PLoS One. 2012;7(1):e29641. doi:10.1371/journal.pone.0029641
   PubMed Web of Science ®Google Scholar
• Sun P, Knezovic A, Parlak M, et al. Long-term effects of intracerebroventricular streptozotocin treatment on adult neurogenesis in the rat hippocampus. Curr Alzheimer Res. 2015;12(8):772–784. doi:10.2174/1567205012666150710112147
   PubMed Web of Science ®Google Scholar
• Wang B, Jin K. Current perspectives on the link between neuroinflammation and neurogenesis. Metab Brain Dis. 2015;30(2):355–365. doi:10.1007/s11011-014-9523-6
   PubMed Web of Science ®Google Scholar
• Bassani TB, Turnes JM, Moura EL, et al. Effects of curcumin on short-term spatial and recognition memory, adult neurogenesis and neuroinflammation in a streptozotocin-induced rat model of dementia of Alzheimer’s type. Behav Brain Res. 2017;335:41–54. doi:10.1016/j.bbr.2017.08.014
   PubMed Web of Science ®Google Scholar
• Stefaniak J, O’Brien J. Imaging of neuroinflammation in dementia: a review. J Neurol Neurosurg Psychiatry. 2016;87(1):21–28.
   PubMed Web of Science ®Google Scholar
• Byrne E. Does mitochondrial respiratory chain dysfunction have a role in common neurodegenerative disorders? J Clin Neurosci. 2002;9(5):497–501. doi:10.1054/jocn.2001.0991
   PubMed Web of Science ®Google Scholar
• Vajda FJ. Neuroprotection and neurodegenerative disease. J Clin Neurosci. 2002;9(1):4–8. doi:10.1054/jocn.2001.1027
   Google Scholar
• Agrawal R, Tyagi E, Shukla R, Nath C. A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia. Neuropharmacology. 2009;56(4):779–787. doi:10.1016/j.neuropharm.2009.01.005
   PubMed Web of Science ®Google Scholar
• Grünblatt E, Salkovic‐Petrisic M, Osmanovic J, Riederer P, Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem. 2007;101(3):757–770. doi:10.1111/j.1471-4159.2006.04368.x
   PubMed Web of Science ®Google Scholar
• Sonkusare S, Srinivasan K, Kaul C, Ramarao P. Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. Life Sci. 2005;77(1):1–4. doi:10.1016/j.lfs.2004.10.036
   PubMed Web of Science ®Google Scholar
• Droege W, Kinscherf R. Aberrant insulin receptor signaling and amino acid homeostasis as a major cause of oxidative stress in aging. Antioxid Redox Signal. 2008;10(4):661–678. doi:10.1089/ars.2007.1953
   PubMed Web of Science ®Google Scholar
• Seo JH, Ahn Y, Lee SR, Yeo CY, Hur KC. The major target of the endogenously generated reactive oxygen species in response to insulin stimulation is phosphatase and tensin homolog and not phosphoinositide-3 kinase (PI-3 kinase) in the PI-3 kinase/Akt pathway. Mol Biol Cell. 2005;16(1):348–357. doi:10.1091/mbc.e04-05-0369
   PubMed Web of Science ®Google Scholar
• Mahadev K, Zilbering A, Zhu L, Goldstein BJ. Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances the early insulin action cascade. J Biol Chem. 2001;276(24):21938–21942. doi:10.1074/jbc.C100109200
   PubMed Web of Science ®Google Scholar
• Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell. 2002;9(2):387–399. doi:10.1016/S1097-2765(02)00445-8
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Di Domenico F, Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim Biophys Acta Mol Basis Dis. 2014;1842(9):1693–1706.
   PubMed Web of Science ®Google Scholar
• Aluise CD, Robinson RA, Cai J, Pierce WM, Markesbery WR, Butterfield DA. Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer’s disease: insights into memory loss in MCI. J Alzheimers Dis. 2011;23(2):257–269. doi:10.3233/JAD-2010-101083
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhong C. Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol. 2013;108:21–43. doi:10.1016/j.pneurobio.2013.06.004
   PubMed Web of Science ®Google Scholar
• Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proc Natl Acad Sci. 2009;106(34):14670–14675. doi:10.1073/pnas.0903563106
   PubMed Web of Science ®Google Scholar
• Reddy PH, Tripathi R, Troung Q, et al. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer’s disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta Mol Basis Dis. 2012;1822(5):639–649. doi:10.1016/j.bbadis.2011.10.011
   PubMed Web of Science ®Google Scholar
• Velazquez R, Tran A, Ishimwe E, et al. Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer’s disease. Neurobiol Aging. 2017;58:1–13. doi:10.1016/j.neurobiolaging.2017.06.003
   PubMed Web of Science ®Google Scholar
• Kim YG, Jeon JY, Kim HJ, et al. Risk of dementia in older patients with type 2 diabetes on dipeptidyl-peptidase IV inhibitors versus sulfonylureas: a real-world population-based cohort study. J Clin Med. 2018;8(1):28. doi:10.3390/jcm8010028
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61:661–666. doi:10.1001/archneur.61.5.661
   PubMed Web of Science ®Google Scholar
• Peila R, Rodriguez BL, Launer LJ, Honolulu-Asia AS. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 2002;51:1256–1262. doi:10.2337/diabetes.51.4.1256
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Schneider JA, Wilson RS, et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology. 2006;67(11):1960–1965. doi:10.1212/01.wnl.0000247053.45483.4e
   PubMed Web of Science ®Google Scholar
• Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999;53(9):1937–1942. doi:10.1212/WNL.53.9.1937
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang M-X, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004;63(7):1187–1192. doi:10.1212/01.WNL.0000140292.04932.87
   PubMed Web of Science ®Google Scholar
• MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord. 2002;14(2):77–83. doi:10.1159/000064928
   PubMed Web of Science ®Google Scholar
• Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1998;50:164–168. doi:10.1212/WNL.50.1.164
   PubMed Web of Science ®Google Scholar
• Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology. 2004;63(7):1181–1186. doi:10.1212/01.WNL.0000140291.86406.D1
   PubMed Web of Science ®Google Scholar
• Schnaider Beeri M, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004;63(10):1902–1907. doi:10.1212/01.WNL.0000144278.79488.DD
   PubMed Web of Science ®Google Scholar
• Bruce DG, Davis WA, Casey GP, et al. Severe hypoglycaemia and cognitive impairment in older patients with diabetes: the Fremantle Diabetes Study. Diabetologia. 2009;52:1808–1815. doi:10.1007/s00125-009-1437-1
   PubMed Web of Science ®Google Scholar
• Rönnemaa E, Zethelius B, Sundelöf J, et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology. 2008;71(14):1065–1071. doi:10.1212/01.wnl.0000310646.32212.3a
   PubMed Web of Science ®Google Scholar
• Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301(15):1565–1572. doi:10.1001/jama.2009.460
   PubMed Web of Science ®Google Scholar
• Lin Z, Tian H, Lam KS, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013;17(5):779–789. doi:10.1016/j.cmet.2013.04.005
   PubMed Web of Science ®Google Scholar
• Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013;173(14):1300–1306. doi:10.1001/jamainternmed.2013.6176
   PubMed Web of Science ®Google Scholar
• Chin SO, Rhee SY, Chon S, et al. Hypoglycemia is associated with dementia in elderly patients with type 2 diabetes mellitus: an analysis based on the Korea National Diabetes Program Cohort. Diabetes Res Clin Pract. 2016;122:54–61. doi:10.1016/j.diabres.2016.09.027
   PubMed Web of Science ®Google Scholar
• Mehta HB, Mehta V, Goodwin JS. Association of hypoglycemia with subsequent dementia in older patients with type 2 diabetes mellitus. J Gerontol Series A Biomed Sci Med Sci. 2017;72(8):1110–1116.
   PubMed Web of Science ®Google Scholar
• Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta‐analysis of longitudinal studies. Intern Med J. 2012;42:484–491. doi:10.1111/j.1445-5994.2012.02758.x
   PubMed Web of Science ®Google Scholar
• Feinkohl I, Aung PP, Keller M, et al.; Edinburgh Type 2 Diabetes Study (ET2DS) Investigators. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2014;37(2):507–515. doi:10.2337/dc13-1384
   PubMed Web of Science ®Google Scholar
• Smolina K, Wotton CJ, Goldacre MJ. Risk of dementia in patients hospitalized with type 1 and type 2 diabetes in England, 1998–2011: A retrospective national record linkage cohort study. Diabetologia. 2015;58:942–950. doi:10.1007/s00125-015-3515-x
   PubMed Web of Science ®Google Scholar
• Aung PP, Strachan MW, Frier BM, Butcher I, Deary IJ, Price JF. Severe hypoglycaemia and late-life cognitive ability in older people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabet Med. 2012;29(3):328–336. doi:10.1111/j.1464-5491.2011.03505.x
   PubMed Web of Science ®Google Scholar
• Matsuzaki T, Sasaki K, Tanizaki Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology. 2010;75(9):764–770. doi:10.1212/WNL.0b013e3181eee25f
   PubMed Web of Science ®Google Scholar
• Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: a meta‐analysis of prospective observational studies. J Diabetes Investig. 2013;4:640–650. doi:10.1111/jdi.12087
   PubMed Web of Science ®Google Scholar
• Cukierman T, Gerstein H, Williamson J. Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460–2469. doi:10.1007/s00125-005-0023-4
   PubMed Web of Science ®Google Scholar
• Kim YG, Park DG, Moon SY, et al. Hypoglycemia and dementia risk in older patients with type 2 diabetes mellitus: a propensity-score matched analysis of a population-based cohort study. Diabetes Metab J. 2020;44(1):125–133. doi:10.4093/dmj.2018.0260
   PubMed Web of Science ®Google Scholar
• Lin CH, Sheu WH. Hypoglycaemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up study. J Intern Med. 2013;273(1):102–110. doi:10.1111/joim.12000
   PubMed Web of Science ®Google Scholar
• Han WN, Hölscher C, Yuan L, et al. Liraglutide protects against amyloid-beta protein-induced impairment of spatial learning and memory in rats. Neurobiol Aging. 2013;34(2):576–588. doi:10.1016/j.neurobiolaging.2012.04.009
   PubMed Web of Science ®Google Scholar
• Kelly P, McClean PL, Ackermann M, Konerding MA, Hölscher C, Mitchell CA. Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with liraglutide. Microcirculation. 2015;22(2):133–145. doi:10.1111/micc.12186
   PubMed Web of Science ®Google Scholar
• Claxton A, Baker LD, Hanson A, et al. Long acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia. J Alzheimers Dis. 2015;45(4):1269–1270. doi:10.3233/JAD-159002
   PubMed Web of Science ®Google Scholar
• Gejl M, Gjedde A, Egefjord L, et al. In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled Double-Blind Clinical Trial. Front Aging Neurosci. 2016;8:108. doi:10.3389/fnagi.2016.00108
   PubMed Web of Science ®Google Scholar
• Isik AT, Soysal P, Yay A, Usarel C. The effects of sitagliptin, a DPP4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer’s disease. Diabetes Res Clin Pract. 2017;123:192–198.
   PubMed Web of Science ®Google Scholar
• Bohlken J, Jacob L, Kostev K. Association between the use of antihyperglycemic drugs and dementia risk: a case-control study. J Alzheimers Dis. 2018;66(2):725–732. doi:10.3233/JAD-180808
   PubMed Web of Science ®Google Scholar
• Lu CH, Yang CY, Li CY, Hsieh CY, Ou HT. Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. Diabetologia. 2018;61(3):562–573. doi:10.1007/s00125-017-4499-5
   PubMed Web of Science ®Google Scholar
• Tseng CH. Pioglitazone reduces dementia risk in patients with type 2 diabetes mellitus: a retrospective cohort analysis. J Clin Med. 2018;7(10):306. doi:10.3390/jcm7100306
   PubMed Web of Science ®Google Scholar
• Bailey JM, Ghaly M, Barrett AC, Hafez S, Coucha MM, Abdelsaid MA. GLP-1 Agonists Improve Cerebrovascular Integrity and Vascular Induced Cognitive Impairment and Dementia Beyond Glycemic Control via Restoration of Brain Pericytes Functions in Diabetic Mice. Stroke. 2020;51(Suppl_1):A39–A39. doi:10.1161/str.51.suppl_1.39
   Google Scholar
• Liu J, Yin F, Zheng X, Jing J, Hu Y. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Int. 2007;51(6–7):361–369. doi:10.1016/j.neuint.2007.04.021
   PubMed Web of Science ®Google Scholar
• Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664–1675. PMID: 28781108. doi:10.1016/S0140-6736(17)31585-4
   PubMed Web of Science ®Google Scholar
• Heneka MT, Fink A, Doblhammer G. Effect of pioglitazone medication on the incidence of dementia. Ann Neurol. 2015;78(2):284–294. doi:10.1002/ana.24439
   PubMed Web of Science ®Google Scholar
• Long-Smith CM, Manning S, McClean PL, et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signaling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer’s disease. Neuromolecular Med. 2013;15(1):102–114. doi:10.1007/s12017-012-8199-5
   PubMed Web of Science ®Google Scholar
• McClean PL, Parthsarathy V, Faivre E, Hölscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci. 2011;31(17):6587–6594. doi:10.1523/JNEUROSCI.0529-11.2011
   PubMed Web of Science ®Google Scholar
• Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease-associated Ab oligomers. J Clin Invest. 2012;122:1339–1353. doi:10.1172/JCI57256
   PubMed Web of Science ®Google Scholar
• Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res. 2003;72(5):603–612. doi:10.1002/jnr.10611
   PubMed Web of Science ®Google Scholar
• Gilman CP, Perry T, Furukawa K, Grieg NH, Egan JM, Mattson MP. Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J Neurochem. 2003;87(5):1137–1144. doi:10.1046/j.1471-4159.2003.02073.x
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:7771. doi:10.1136/bmj.d7771
   PubMed Web of Science ®Google Scholar
• Chin-Hsiao T. Metformin and the risk of dementia in type 2 diabetes patients. Aging Dis. 2019;10(1):37–48. 27. doi:10.14336/AD.2017.1202
   PubMed Web of Science ®Google Scholar